Proactive Investors - Run By Investors For Investors

Achieve Life Sciences shares soar after results suggest that its anti-smoking aid can be taken with other drugs

Its drug cytisine is intended to reduce nicotine cravings and withdrawal symptoms in smokers
Cigarette
The study suggests that the drug may be taken safely alongside other medication

Achieve Life Sciences Inc (NASDAQ:ACHV) shares surged after data showed that its smoking cessation aid is unlikely to interact negatively with other drugs.

A study into its drug cytisine found no clinically significant interaction with the enzymes responsible for drug metabolism or drug transporters. Results suggest that cytisine can be used alongside other medications without changing the dose of either.

Shares of the Seattle-based company jumped nearly 50% to US$5.57 in Tuesday pre-market trading.

Cytisine is designed to target a nicotine receptor to reduce nicotine cravings and withdrawal symptoms.

“Smokers are as likely as anyone to take medications for a range of conditions. These results suggest that cytisine is unlikely to interfere with their ability to take other medications safely and should help to minimize restrictions on the eligibility of subjects in our forthcoming clinical trials expected to commence later this year," said chief science officer Anthony Clarke in a press statement.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

 

View full ACHV profile View Profile

Achieve Life Sciences Inc Timeline

Related Articles

Platinum
January 04 2019
In its outlook for 2019, the firm said the focus was now “not only on continuous improvements in feed grade and recoveries but on expanding the business into new jurisdictions”
Kazakhstan
November 20 2018
Borko Moric will succeed Parilla as chief executive officer. Bojan Moric will become the company's chief operations officer
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use